Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

121. Safety of renal biopsy for patients taking aspirin

Safety of renal biopsy for patients taking aspirin Safety of renal biopsy for patients taking aspirin Safety of renal biopsy for patients taking aspirin Mitchell MD, Berns JS, Rudnick MR, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Berns JS, Rudnick MR, Umscheid CA. Safety of renal biopsy for patients taking aspirin. Philadelphia (...) : Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Aspirin; Biopsys; Kidney Neoplasms; Safety Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber 32015000553 Date

Health Technology Assessment (HTA) Database.2014

122. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication Final Update Summary: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Final Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive (...) Medication Release Date: September 2014 Recommendation Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia Population Recommendation Grade Pregnant Women Who Are At High Risk for Preeclampsia The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. ( ) Related Information for Consumers Related Information for Health Professionals There is no related information

U.S. Preventive Services Task Force2014

123. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, Grove A, Gurung B (...) , Morrow S, Clarke A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, Grove A, Gurung B, Morrow S, Clarke A. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews. Health Technology Assessment 2013

Health Technology Assessment (HTA) Database.2013

125. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. BACKGROUND: Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant. OBJECTIVE: To examine the association between long-term, alternate-day, low-dose aspirin and cancer in healthy women. DESIGN: Observational follow-up of a randomized trial. SETTING: Female health professionals. PARTICIPANTS (...) : 39,876 women aged 45 years or older in the Women's Health Study (ClinicalTrials.gov: NCT00000479 ), 33 682 of whom continued observational follow-up. INTERVENTION: 100 mg of alternate-day aspirin or placebo through March 2004, with a median 10-year follow-up. Posttrial follow-up continued through March 2012. MEASUREMENTS: Cancer incidence. RESULTS: A total of 5071 cancer cases (including 2070 breast, 451 colorectal, and 431 lung cancer cases) and 1391 cancer deaths were confirmed. Over the entire

Annals of Internal Medicine2013

126. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. BACKGROUND: Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone. METHODS: In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours after the onset (...) of minor ischemic stroke or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat

NEJM2013

127. Aspirin use and risk of colorectal cancer according to BRAF mutation status.

Aspirin use and risk of colorectal cancer according to BRAF mutation status. IMPORTANCE: Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF-wild-type neoplastic cells. OBJECTIVE: To examine whether the association of aspirin intake (...) with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation. DESIGN AND SETTING: We collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study (from 1980) and the Health Professionals Follow-up Study (from 1986) until July 1, 2006, for cancer incidence and until January 1, 2012, for cancer mortality. Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute hazard ratios (HRs

JAMA2013 Full Text: Link to full Text with Trip Pro

128. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.

Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. BACKGROUND: The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. OBJECTIVE: To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. DESIGN: Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically (...) days of dalteparin prophylaxis after elective THA, patients were randomly assigned to 28 days of dalteparin (n = 400) or aspirin (n = 386). MEASUREMENTS: Symptomatic VTE confirmed by objective testing (primary efficacy outcome) and bleeding. RESULTS: Five of 398 patients (1.3%) randomly assigned to dalteparin and 1 of 380 (0.3%) randomly assigned to aspirin had VTE (absolute difference, 1.0 percentage point [95% CI, -0.5 to 2.5 percentage points]). Aspirin was noninferior (P < 0.001

Annals of Internal Medicine2013

129. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women

Effect of low-dose aspirin on functional outcome from cerebral vascular events in women 23306328 2013 01 21 2013 03 11 2016 12 03 1524-4628 44 2 2013 Feb Stroke Stroke Effect of low-dose aspirin on functional outcome from cerebral vascular events in women. 432-6 10.1161/STROKEAHA.112.672451 Although aspirin is effective in prevention of stroke, fewer studies have examined the impact of aspirin on stroke morbidity. The Women's Health Study is a completed randomized, placebo-controlled trial (...) designed to test the effect of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer, which enrolled 39 876 women. We used multinomial logistic regression to evaluate the relationship between randomized aspirin assignment and functional outcomes from stroke. Possible functional outcomes were neither stroke nor transient ischemic attack (TIA), modified Rankin scale (mRS) score 0 to 1, 2 to 3, and 4 to 6. After a mean of 9.9 years of follow-up, 460 confirmed

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

130. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. BACKGROUND: If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared (...) with clopidogrel plus aspirin. METHODS: We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008, to November, 2011, adults receiving oral anticoagulants and undergoing PCI were assigned clopidogrel alone (double therapy) or clopidogrel plus aspirin (triple therapy). The primary outcome was any bleeding episode within 1 year of PCI, assessed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769938

Lancet2013

131. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism.

Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. ACP Journal Club. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager (...) Format Create File 1 selected item: 23552619 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2013 Mar 19;158(6):JC2. doi: 10.7326/0003-4819-158-6-201303190-02002. ACP Journal Club. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. . Comment on [N Engl J Med. 2012] PMID: 23552619 DOI

Annals of Internal Medicine2013

132. Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy.

Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Failure of aspirin plus dipyridam... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1992 ) Volume: 116 , Issue: 9 , Pages: 731-736 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To evaluate therapy with aspirin plus dipyridamole in reducing restenosis after carotid endarterectomy (...) . PATIENTS: A total of 163 patients having 175 surgical carotid endarterectomies. INTERVENTION: Eighty-three patients (90 endarterectomies) were randomly assigned to receive oral aspirin, 325 mg, plus dipyridamole, 75 mg, beginning 12 hours preoperatively, followed by a second dose administered within 8 hours after the operation, and given three times daily thereafter for 1 year. Eighty patients (85 endarterectomies) received placebo medication that was identical in appearance to the study drugs

Annals of Internal Medicine2013

133. A prospective study of aspirin use and the risk for colorectal adenoma.

A prospective study of aspirin use and the risk for colorectal adenoma. A prospective study of aspirin us... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2004 ) Volume: 140 , Issue: 3 , Pages: 157-166 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk (...) for recurrent colorectal adenoma. However, the effect of dose and duration of use, particularly in an average-risk population, is not well understood. OBJECTIVE: To examine the influence of dose and duration of aspirin use in the primary prevention of colorectal adenoma. DESIGN: Prospective cohort study. SETTING: Nurses' Health Study. PARTICIPANTS: 27 077 women, 34 to 77 years of age, without a history of adenoma, cancer, inflammatory bowel disease, or familial polyposis, who underwent lower endoscopy

Annals of Internal Medicine2013

134. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Aspirin to prevent cardiovascular... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2009 ) Volume: 150 , Issue: 6 , Pages: 379-386 PubMed: Available from or Find this paper at: Abstract BACKGROUND: The optimal aspirin dose for the prevention of cardiovascular events (...) remains controversial. OBJECTIVE: To assess the incidence of and risk factors for adverse clinical outcomes by investigator-determined aspirin dose in a primary prevention trial. DESIGN: Post hoc observational analyses of data from a double-blind, placebo-controlled, randomized trial. SETTING: Outpatient. PATIENTS: 15 595 patients with cardiovascular disease or multiple risk factors. INTERVENTION: Clopidogrel, 75 mg/d, or placebo, with aspirin, 75 to 162 mg/d, as selected by the investigators

Annals of Internal Medicine2013

135. Annals of Internal Medicine Article Aspirin to Prevent Cardiovascular Disease : The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding

Annals of Internal Medicine Article Aspirin to Prevent Cardiovascular Disease : The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding Annals of Internal Medicine Artic... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2009 ) Volume: 150 , Issue: 1539-3704 (Electronic) LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't RN - 0 (Platelet Aggregation (...) Inhibitors) RN - 50-78-2 (Aspirin) RN - 55142-85-3 (Ticlopidine) RN - 90055-48-4 (clopidogrel) SB - AIM SB - IM , Pages: 379-386 Find this paper at: Abstract Background: The optimal aspirin dose for the prevention of cardiovascular events remains controversial. Objective: To assess the incidence of and risk factors for adverse clinical outcomes by investigator-determined aspirin dose in a primary prevention trial. Design: Post hoc observational analyses of data from a double-blind, placebo-controlled

Annals of Internal Medicine2013

136. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury.

Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Dose effects of aspirin on gastri... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1994 ) Volume: 120 , Issue: 3 , Pages: 184-189 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To determine if a dose of aspirin exists that might inhibit thromboxane-dependent platelet function without causing (...) gastric mucosal injury, we studied the effects of a wide range of doses of aspirin (3 mg/d to 2600 mg/d) on gastric juice prostaglandins (PGE2 and PGF2 alpha), on serum thromboxane B2, and on stomach mucosal injury as reflected by gastric juice hemoglobin and DNA concentrations. DESIGN: A randomized, placebo-controlled study. SETTING: Research laboratory at a Veterans Affairs medical center. PARTICIPANTS: 16 healthy volunteers (5 men and 11 women). INTERVENTION: In the first part of the study

Annals of Internal Medicine2013

137. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study.

Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Aspirin use and colorectal cancer... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1998 ) Volume: 128 , Issue: 9 , Pages: 713-720 PubMed: Available from or Find this paper at: Abstract BACKGROUND: In contrast to most observational studies, the randomized Physicians' Health Study found (...) no association between aspirin use and colorectal cancer after 5 years. OBJECTIVE: To determine the effect of randomly assigned aspirin treatment and self-selected aspirin use on the incidence of colorectal cancer after 12 years and to identify factors influencing the self-selection of regular aspirin use. Design: Randomized clinical trial and prospective cohort study. SETTING: Male physicians throughout the United States. Patients: 22071 healthy male physicians who were 40 to 84 years of age in 1982

Annals of Internal Medicine2013

138. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of clopidogrel plus aspirin, compared with aspirin alone, for the prevention of stroke in patients with uncomplicated atrial fibrillation. The authors concluded

NHS Economic Evaluation Database.2013

139. Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding

Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding UTCAT2440, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding Clinical Question In a patient undergoing oral surgery, can vitamin E in combination with aspirin pose increased risk of postoperative bleeding? Clinical Bottom Line Both articles indicate the enhanced (...) anti-platelet effect of aspirin in combination with vitamin E. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Celestini/2002 Healthy Human (blood) taking no medication. In vitro study Key results The anti-platelet aggregation effect of acetylsalicylic acid was enhanced in presence of vitamin E, by increasing the NO(nitrous oxide) production 42 fold(P #2) Gonzalez-Correa/2005 Whole blood from healthy

UTHSCSA Dental School CAT Library2013

140. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. 23415013 2013 04 01 2013 04 08 2015 06 16 1474-547X 381 9872 2013 Mar 30 Lancet (London, England) Lancet Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. 1107-15 10.1016/S0140 (...) -6736(12)62177-1 S0140-6736(12)62177-1 If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared with clopidogrel plus aspirin. We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008

Lancet2013